{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["42(4)"],"submitter":["Michaeli DT"],"funding":["Medizinische Fakultät Mannheim der Universität Heidelberg"],"pubmed_abstract":["<h4>Background and objectives</h4>In South Africa, the prevalence of human papillomavirus (HPV) and associated diseases, such as cervical cancer and genital warts, is among the highest in the world. This study evaluates the cost-effectiveness of bivalent, quadrivalent, and nonavalent HPV vaccination for 9- to 14-year-old girls from the South African healthcare system perspective.<h4>Methods</h4>A Markov model portraying the natural HPV disease progression from high-risk infection to cervical intraepithelial neoplasia (CIN) I, CIN II/III, or cervical cancer and from low-risk infection to genital warts was built. Transition probability, utility, and efficacy data were sourced from peer-reviewed literature. Vaccination costs were calculated based on the World Health Organization (WHO) guideli"],"journal":["Clinical drug investigation"],"pagination":["333-343"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8989937"],"repository":["biostudies-literature"],"pubmed_title":["Cost-Effectiveness of Bivalent, Quadrivalent, and Nonavalent HPV Vaccination in South Africa."],"pmcid":["PMC8989937"],"pubmed_authors":["Zhang W","Marcus SM","Michaeli JC","Michaeli T","Michaeli DT","Stoycheva S"],"additional_accession":[]},"is_claimable":false,"name":"Cost-Effectiveness of Bivalent, Quadrivalent, and Nonavalent HPV Vaccination in South Africa.","description":"<h4>Background and objectives</h4>In South Africa, the prevalence of human papillomavirus (HPV) and associated diseases, such as cervical cancer and genital warts, is among the highest in the world. This study evaluates the cost-effectiveness of bivalent, quadrivalent, and nonavalent HPV vaccination for 9- to 14-year-old girls from the South African healthcare system perspective.<h4>Methods</h4>A Markov model portraying the natural HPV disease progression from high-risk infection to cervical intraepithelial neoplasia (CIN) I, CIN II/III, or cervical cancer and from low-risk infection to genital warts was built. Transition probability, utility, and efficacy data were sourced from peer-reviewed literature. Vaccination costs were calculated based on the World Health Organization (WHO) guideli","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Apr","modification":"2025-04-22T19:12:26.566Z","creation":"2025-04-06T02:39:07.6Z"},"accession":"S-EPMC8989937","cross_references":{"pubmed":["35294726"],"doi":["10.1007/s40261-022-01138-6"]}}